Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Pancreatic Cancer Health Center

Font Size

Chemo Combination May Treat Pancreatic Cancer

Small Study Shows Survival Rates Better With Mix of Chemotherapy Drugs

About Pancreatic Cancer continued...

In the PEFG group, 60% survived four months without their cancer progressing, compared with 28% of the gemcitabine group. The PEFG group also had a higher overall survival rate at one year than the gemcitabine group (39.5% compared with 21.3%).

After two years, five PEFG patients were still alive. So was one person in the gemcitabine group.

"The proportion of patients with one-year and two-year survival was greater in the PEFG group than in the gemcitabine group," says the study.

Side Effects, Quality of Life

Side effects, relating to blood abnormalities from the cancer-fighting medications, "were significantly higher in patients assigned combination treatment than in those assigned gemcitabine, but were of short duration and were manageable," say the researchers.

As for quality of life, Reni and colleagues say this: "Although conventional statistical testing was not done, we noted that patients allocated PEFG were 20% to 44% more likely to obtain a clinically relevant improvement in scores for emotional functioning, overall quality of life, cognitive measures, pain, fatigue, indigestion, dyspnoea, appetite loss, and flatulence than those allocated gemcitabine."

The gemcitabine group reportedly fared better in two regards. "Patients in the gemcitabine group had better scores for sexual function and body image than did those in the PEFG group," says the study.

Treatment of the Future?

Cautioning that larger studies are needed, Reni and colleagues say their findings are nevertheless important "because PEFG had manageable toxic effects, did not negatively affect quality of life, and maintained a clinically and statistically relevant outcome advantage compared to standard treatment."

"Accordingly, PEFG might be a feasible and effective first-line treatment for patients with locally advanced or metastatic pancreatic adenocarcinoma," says the study.

1 | 2

Today on WebMD

human pancreas
Do you know what they are?
man with a doctor
Our health check will steer you in the right direction.
sauteed cherry tomatoes
Fight cancer one plate at a time.
Lung cancer xray
See it in pictures, plus read the facts.
Integrative Medicine Cancer Quiz
Patrick Swayzes Widow Healing From Loss
Pets Improve Your Health
Resolved To Quit Smoking